▶ 調査レポート

抗菌(薬剤)耐性の世界市場レポート2020

• 英文タイトル:Global Antibacterial (Drug) Resistance Sales Market Report 2020

QYResearchが調査・発行した産業分析レポートです。抗菌(薬剤)耐性の世界市場レポート2020 / Global Antibacterial (Drug) Resistance Sales Market Report 2020 / 20QY06-05511資料のイメージです。• レポートコード:20QY06-05511
• 出版社/出版日:QYResearch / 2020年6月3日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、147ページ
• 納品方法:Eメール(受注後2~3営業日)
• 産業分類:医薬品・医療
• 販売価格(消費税別)
  Single User¥592,000 (USD4,000)▷ お問い合わせ
  Multi User¥888,000 (USD6,000)▷ お問い合わせ
  Enterprise License¥1,184,000 (USD8,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社の当調査資料では、抗菌(薬剤)耐性のグローバル市場について種類別(テラバンシン(Vibativ)、セフタロリンフォサミル(Teflaro / Zinforo)、フィダキソマイシン(Dificid / Dificlir)、セフトビプロレメドカリル(Zevtera / Zeftera / Mabelio)、ダルババンシン(Dalvance / Xydalba)、テジゾリドリン酸エステル (Sivextro)、オリタバンシン (Orbactiv/ Nuvocid) 、セフトロザンタゾバクタム(Zerbaxa)、セフタジジムアビバクタム(Avycaz / Zavicefta)、フェーズIII薬)、用途別(複雑性尿路感染症(CUTI)、複雑性腹腔内感染症(CIAI)、血流感染症(BSI)、クロストリジウムディフィシル感染症(CDI)、急性細菌性皮膚および皮膚構造感染症(ABSSSI)、病院後天性細菌性肺炎/換気/ VABP)、コミュニティ取得細菌性肺炎(CABP))、地域別(北米、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2015年~2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。

・抗菌(薬剤)耐性市場の概要
・世界の主要地域別抗菌(薬剤)耐性市場規模2015-2026
・主要プレイヤーの競争状況・市場シェア
・世界の抗菌(薬剤)耐性市場規模2015-2026:種類別(テラバンシン(Vibativ)、セフタロリンフォサミル(Teflaro / Zinforo)、フィダキソマイシン(Dificid / Dificlir)、セフトビプロレメドカリル(Zevtera / Zeftera / Mabelio)、ダルババンシン(Dalvance / Xydalba)、テジゾリドリン酸エステル (Sivextro)、オリタバンシン (Orbactiv/ Nuvocid) 、セフトロザンタゾバクタム(Zerbaxa)、セフタジジムアビバクタム(Avycaz / Zavicefta)、フェーズIII薬)
・世界の抗菌(薬剤)耐性市場規模2015-2026:用途別(複雑性尿路感染症(CUTI)、複雑性腹腔内感染症(CIAI)、血流感染症(BSI)、クロストリジウムディフィシル感染症(CDI)、急性細菌性皮膚および皮膚構造感染症(ABSSSI)、病院後天性細菌性肺炎/換気/ VABP)、コミュニティ取得細菌性肺炎(CABP))
・抗菌(薬剤)耐性の北米市場規模2015-2020
・抗菌(薬剤)耐性のヨーロッパ市場規模2015-2020
・抗菌(薬剤)耐性の中国市場規模2015-2020
・抗菌(薬剤)耐性の日本市場規模2015-2020
・抗菌(薬剤)耐性の東南アジア市場規模2015-2020
・抗菌(薬剤)耐性のインド市場規模2015-2020
・主要プレイヤーの企業情報:事業概要・売上・企業動向
(Melinta Therapeutics、Allergan、Merck、Abbott Laboratories、Pfizer、GSK、PENDOPHARM、Absynth Biologics、Achaogen、Acino Holdings、Aventis Pharma、Austell Laboratories、Assembly Biosciences、Arpida、Demuris、Evolva Holding、ContraFect、Cerexa、InterMune、Isis Pharmaceuticals、Lyndra、Microbecide、Morphochem、Nabriva Therapeutics、NanoSafe Coatings、Novexel、Osel、VenatoRx Pharmaceuticals、AAIPharma Services、ANTABIO)
・抗菌(薬剤)耐性の製造コスト分析
・販売チャネル、流通業者、顧客
・抗菌(薬剤)耐性の市場動向・機会・課題
・調査の結論

Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.

Market Analysis and Insights: Global Antibacterial (Drug) Resistance Market
The global Antibacterial (Drug) Resistance market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Antibacterial (Drug) Resistance Scope and Market Size
The global Antibacterial (Drug) Resistance market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antibacterial (Drug) Resistance market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Antibacterial (Drug) Resistance market is segmented into
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS

Segment by Application, the Antibacterial (Drug) Resistance market is segmented into
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
The Antibacterial (Drug) Resistance market is analysed and market size information is provided by regions (countries). Segment by Application, the Antibacterial (Drug) Resistance market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Antibacterial (Drug) Resistance Market Share Analysis
Antibacterial (Drug) Resistance market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Antibacterial (Drug) Resistance business, the date to enter into the Antibacterial (Drug) Resistance market, Antibacterial (Drug) Resistance product introduction, recent developments, etc.
The major vendors covered:
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO

レポート目次

Table of Contents

1 Antibacterial (Drug) Resistance Market Overview
1.1 Antibacterial (Drug) Resistance Product Scope
1.2 Antibacterial (Drug) Resistance Segment by Type
1.2.1 Global Antibacterial (Drug) Resistance Sales by Type (2020-2026)
1.2.2 Telavancin (Vibativ)
1.2.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
1.2.4 Fidaxomicin (Dificid / Dificlir)
1.2.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
1.2.6 Dalbavancin (Dalvance/ Xydalba)
1.2.7 Tedizolid Phosphate (Sivextro)
1.2.8 Oritavancin (Orbactiv/ Nuvocid)
1.2.9 Ceftolozane-Tazobactam (Zerbaxa)
1.2.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
1.2.11 PHASE III DRUGS
1.3 Antibacterial (Drug) Resistance Segment by Application
1.3.1 Global Antibacterial (Drug) Resistance Sales Comparison by Application (2020-2026)
1.3.2 Complicated Urinary Tract Infection (CUTI)
1.3.3 Complicated Intra-Abdominal Infections (CIAI)
1.3.4 Blood Stream Infections (BSI)
1.3.5 Clostridium Difficile Infections (CDI)
1.3.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
1.3.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.3.8 Community Acquired Bacterial Pneumonia (CABP)
1.4 Antibacterial (Drug) Resistance Market Estimates and Forecasts (2015-2026)
1.4.1 Global Antibacterial (Drug) Resistance Sales Growth Rate (2015-2026)
1.4.2 Global Antibacterial (Drug) Resistance Revenue and Growth Rate (2015-2026)
1.4.3 Global Antibacterial (Drug) Resistance Price Trends (2015-2026)

2 Antibacterial (Drug) Resistance Estimate and Forecast by Region
2.1 Global Antibacterial (Drug) Resistance Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Antibacterial (Drug) Resistance Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Antibacterial (Drug) Resistance Sales Market Share by Region (2015-2020)
2.2.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2015-2020)
2.3 Global Antibacterial (Drug) Resistance Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Antibacterial (Drug) Resistance Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Antibacterial (Drug) Resistance Estimates and Projections (2015-2026)
2.4.2 Europe Antibacterial (Drug) Resistance Estimates and Projections (2015-2026)
2.4.3 China Antibacterial (Drug) Resistance Estimates and Projections (2015-2026)
2.4.4 Japan Antibacterial (Drug) Resistance Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Antibacterial (Drug) Resistance Estimates and Projections (2015-2026)
2.4.6 India Antibacterial (Drug) Resistance Estimates and Projections (2015-2026)
3 Global Antibacterial (Drug) Resistance Competition Landscape by Players
3.1 Global Top Antibacterial (Drug) Resistance Players by Sales (2015-2020)
3.2 Global Top Antibacterial (Drug) Resistance Players by Revenue (2015-2020)
3.3 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibacterial (Drug) Resistance as of 2019)
3.4 Global Antibacterial (Drug) Resistance Average Price by Company (2015-2020)
3.5 Manufacturers Antibacterial (Drug) Resistance Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Antibacterial (Drug) Resistance Players (Opinion Leaders)
4 Global Antibacterial (Drug) Resistance Market Size by Type
4.1 Global Antibacterial (Drug) Resistance Historic Market Review by Type (2015-2020)
4.1.1 Global Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
4.1.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2015-2020)
4.1.3 Global Antibacterial (Drug) Resistance Price by Type (2014-2020)
4.2 Global Antibacterial (Drug) Resistance Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Type (2021-2026)
4.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Type (2021-2026)
4.2.3 Global Antibacterial (Drug) Resistance Price Forecast by Type (2021-2026)
5 Global Antibacterial (Drug) Resistance Market Size by Application
5.1 Global Antibacterial (Drug) Resistance Historic Market Review by Application (2015-2020)
5.1.1 Global Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)
5.1.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2015-2020)
5.1.3 Global Antibacterial (Drug) Resistance Price by Application (2015-2020)
5.2 Global Antibacterial (Drug) Resistance Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Application (2021-2026)
5.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Application (2021-2026)
5.2.3 Global Antibacterial (Drug) Resistance Price Forecast by Application (2021-2026)

3 North America Antibacterial (Drug) Resistance Market Facts & Figures
3.2 North America Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
3.3 North America Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
3.4 North America Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)

4 Europe Antibacterial (Drug) Resistance Market Facts & Figures
4.2 Europe Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
4.3 Europe Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
4.4 Europe Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)

5 China Antibacterial (Drug) Resistance Market Facts & Figures
5.2 China Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
5.3 China Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
5.4 China Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)

6 Japan Antibacterial (Drug) Resistance Market Facts & Figures
6.2 Japan Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
6.3 Japan Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
6.4 Japan Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)

7 Southeast Asia Antibacterial (Drug) Resistance Market Facts & Figures
7.2 Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)

8 India Antibacterial (Drug) Resistance Market Facts & Figures
8.2 India Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
8.3 India Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
8.4 India Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Antibacterial (Drug) Resistance Business
12.1 Melinta Therapeutics
12.1.1 Melinta Therapeutics Antibacterial (Drug) Resistance Corporation Information
12.1.2 Melinta Therapeutics Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
12.1.5 Melinta Therapeutics Recent Development
12.2 Allergan
12.2.1 Allergan Antibacterial (Drug) Resistance Corporation Information
12.2.2 Allergan Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Allergan Antibacterial (Drug) Resistance Products Offered
12.2.5 Allergan Recent Development
12.3 Merck
12.3.1 Merck Antibacterial (Drug) Resistance Corporation Information
12.3.2 Merck Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Merck Antibacterial (Drug) Resistance Products Offered
12.3.5 Merck Recent Development
12.4 Abbott Laboratories
12.4.1 Abbott Laboratories Antibacterial (Drug) Resistance Corporation Information
12.4.2 Abbott Laboratories Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Products Offered
12.4.5 Abbott Laboratories Recent Development
12.5 Pfizer
12.5.1 Pfizer Antibacterial (Drug) Resistance Corporation Information
12.5.2 Pfizer Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Pfizer Antibacterial (Drug) Resistance Products Offered
12.5.5 Pfizer Recent Development
12.6 GSK
12.6.1 GSK Antibacterial (Drug) Resistance Corporation Information
12.6.2 GSK Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.6.4 GSK Antibacterial (Drug) Resistance Products Offered
12.6.5 GSK Recent Development
12.7 PENDOPHARM
12.7.1 PENDOPHARM Antibacterial (Drug) Resistance Corporation Information
12.7.2 PENDOPHARM Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.7.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.7.4 PENDOPHARM Antibacterial (Drug) Resistance Products Offered
12.7.5 PENDOPHARM Recent Development
12.8 Absynth Biologics
12.8.1 Absynth Biologics Antibacterial (Drug) Resistance Corporation Information
12.8.2 Absynth Biologics Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Absynth Biologics Antibacterial (Drug) Resistance Products Offered
12.8.5 Absynth Biologics Recent Development
12.9 Achaogen
12.9.1 Achaogen Antibacterial (Drug) Resistance Corporation Information
12.9.2 Achaogen Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Achaogen Antibacterial (Drug) Resistance Products Offered
12.9.5 Achaogen Recent Development
12.10 Acino Holdings
12.10.1 Acino Holdings Antibacterial (Drug) Resistance Corporation Information
12.10.2 Acino Holdings Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Acino Holdings Antibacterial (Drug) Resistance Products Offered
12.10.5 Acino Holdings Recent Development
12.11 Aventis Pharma
12.11.1 Aventis Pharma Antibacterial (Drug) Resistance Corporation Information
12.11.2 Aventis Pharma Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.11.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Aventis Pharma Antibacterial (Drug) Resistance Products Offered
12.11.5 Aventis Pharma Recent Development
12.12 Austell Laboratories
12.12.1 Austell Laboratories Antibacterial (Drug) Resistance Corporation Information
12.12.2 Austell Laboratories Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Austell Laboratories Antibacterial (Drug) Resistance Products Offered
12.12.5 Austell Laboratories Recent Development
12.13 Assembly Biosciences
12.13.1 Assembly Biosciences Antibacterial (Drug) Resistance Corporation Information
12.13.2 Assembly Biosciences Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Assembly Biosciences Antibacterial (Drug) Resistance Products Offered
12.13.5 Assembly Biosciences Recent Development
12.14 Arpida
12.14.1 Arpida Antibacterial (Drug) Resistance Corporation Information
12.14.2 Arpida Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Arpida Antibacterial (Drug) Resistance Products Offered
12.14.5 Arpida Recent Development
12.15 Demuris
12.15.1 Demuris Antibacterial (Drug) Resistance Corporation Information
12.15.2 Demuris Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Demuris Antibacterial (Drug) Resistance Products Offered
12.15.5 Demuris Recent Development
12.16 Evolva Holding
12.16.1 Evolva Holding Antibacterial (Drug) Resistance Corporation Information
12.16.2 Evolva Holding Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Evolva Holding Antibacterial (Drug) Resistance Products Offered
12.16.5 Evolva Holding Recent Development
12.17 ContraFect
12.17.1 ContraFect Antibacterial (Drug) Resistance Corporation Information
12.17.2 ContraFect Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.17.4 ContraFect Antibacterial (Drug) Resistance Products Offered
12.17.5 ContraFect Recent Development
12.18 Cerexa
12.18.1 Cerexa Antibacterial (Drug) Resistance Corporation Information
12.18.2 Cerexa Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.18.4 Cerexa Antibacterial (Drug) Resistance Products Offered
12.18.5 Cerexa Recent Development
12.19 InterMune
12.19.1 InterMune Antibacterial (Drug) Resistance Corporation Information
12.19.2 InterMune Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.19.4 InterMune Antibacterial (Drug) Resistance Products Offered
12.19.5 InterMune Recent Development
12.20 Isis Pharmaceuticals
12.20.1 Isis Pharmaceuticals Antibacterial (Drug) Resistance Corporation Information
12.20.2 Isis Pharmaceuticals Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.20.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Products Offered
12.20.5 Isis Pharmaceuticals Recent Development
12.21 Lyndra
12.21.1 Lyndra Antibacterial (Drug) Resistance Corporation Information
12.21.2 Lyndra Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.21.4 Lyndra Antibacterial (Drug) Resistance Products Offered
12.21.5 Lyndra Recent Development
12.22 Microbecide
12.22.1 Microbecide Antibacterial (Drug) Resistance Corporation Information
12.22.2 Microbecide Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.22.4 Microbecide Antibacterial (Drug) Resistance Products Offered
12.22.5 Microbecide Recent Development
12.23 Morphochem
12.23.1 Morphochem Antibacterial (Drug) Resistance Corporation Information
12.23.2 Morphochem Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.23.4 Morphochem Antibacterial (Drug) Resistance Products Offered
12.23.5 Morphochem Recent Development
12.24 Nabriva Therapeutics
12.24.1 Nabriva Therapeutics Antibacterial (Drug) Resistance Corporation Information
12.24.2 Nabriva Therapeutics Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.24.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Products Offered
12.24.5 Nabriva Therapeutics Recent Development
12.25 NanoSafe Coatings
12.25.1 NanoSafe Coatings Antibacterial (Drug) Resistance Corporation Information
12.25.2 NanoSafe Coatings Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.25.4 NanoSafe Coatings Antibacterial (Drug) Resistance Products Offered
12.25.5 NanoSafe Coatings Recent Development
12.26 Novexel
12.26.1 Novexel Antibacterial (Drug) Resistance Corporation Information
12.26.2 Novexel Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.26.4 Novexel Antibacterial (Drug) Resistance Products Offered
12.26.5 Novexel Recent Development
12.27 Osel
12.27.1 Osel Antibacterial (Drug) Resistance Corporation Information
12.27.2 Osel Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.27.4 Osel Antibacterial (Drug) Resistance Products Offered
12.27.5 Osel Recent Development
12.28 VenatoRx Pharmaceuticals
12.28.1 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Corporation Information
12.28.2 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.28.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Products Offered
12.28.5 VenatoRx Pharmaceuticals Recent Development
12.29 AAIPharma Services
12.29.1 AAIPharma Services Antibacterial (Drug) Resistance Corporation Information
12.29.2 AAIPharma Services Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.29.4 AAIPharma Services Antibacterial (Drug) Resistance Products Offered
12.29.5 AAIPharma Services Recent Development
12.30 ANTABIO
12.30.1 ANTABIO Antibacterial (Drug) Resistance Corporation Information
12.30.2 ANTABIO Antibacterial (Drug) Resistance Business Overview and Total Revenue
12.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
12.30.4 ANTABIO Antibacterial (Drug) Resistance Products Offered
12.30.5 ANTABIO Recent Development

13 Antibacterial (Drug) Resistance Manufacturing Cost Analysis
13.1 Antibacterial (Drug) Resistance Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Antibacterial (Drug) Resistance
13.4 Antibacterial (Drug) Resistance Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Antibacterial (Drug) Resistance Distributors List
14.3 Antibacterial (Drug) Resistance Customers

15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables

Table 1. Global Antibacterial (Drug) Resistance Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Antibacterial (Drug) Resistance Sales (K Units) Comparison by Application (2020-2026)
Table 3. Global Market Antibacterial (Drug) Resistance Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Antibacterial (Drug) Resistance Sales (K Units) by Region (2015-2020)
Table 5. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2015-2020)
Table 6. Global Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Antibacterial (Drug) Resistance Revenue Share by Region (2015-2020)
Table 8. Global Antibacterial (Drug) Resistance Sales (K Units) Forecast by Region (2021-2026)
Table 9. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Antibacterial (Drug) Resistance Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Antibacterial (Drug) Resistance Revenue Share Forecast by Region (2021-2026)
Table 12. Global Antibacterial (Drug) Resistance (K Units) of Key Companies (2015-2020)
Table 13. Global Antibacterial (Drug) Resistance Sales Share by Company (2015-2020)
Table 14. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Antibacterial (Drug) Resistance Revenue Share by Company (2015-2020)
Table 16. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibacterial (Drug) Resistance as of 2019)
Table 17. Global Antibacterial (Drug) Resistance Average Price (USD/Unit) of Key Company (2015-2020)
Table 18. Manufacturers Antibacterial (Drug) Resistance Manufacturing Sites and Area Served
Table 19. Manufacturers Antibacterial (Drug) Resistance Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Antibacterial (Drug) Resistance Players
Table 22. Global Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 23. Global Antibacterial (Drug) Resistance Sales Share by Type (2015-2020)
Table 24. Global Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Antibacterial (Drug) Resistance Price (K Units) by Type (2015-2020)
Table 26. Global Antibacterial (Drug) Resistance Sales Share by Type (2021-2026)
Table 27. Global Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Antibacterial (Drug) Resistance Revenue Share by Type (2021-2026)
Table 29. Global Antibacterial (Drug) Resistance Price (K Units) by Type (2021-2026)
Table 30. Global Antibacterial (Drug) Resistance Sales (K Units) by Application (2015-2020)
Table 31. Global Antibacterial (Drug) Resistance Sales Share by Application (2015-2020)
Table 32. Global Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Antibacterial (Drug) Resistance Price (K Units) by Application (2015-2020)
Table 34. Global Antibacterial (Drug) Resistance Sales (K Units) by Application (2021-2026)
Table 35. Global Antibacterial (Drug) Resistance Sales Share by Application (2021-2026)
Table 36. Global Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Antibacterial (Drug) Resistance Revenue Share by Application (2021-2026)
Table 38. Global Antibacterial (Drug) Resistance Price (K Units) by Application (2021-2026)
Table 39. United States Antibacterial (Drug) Resistance Sales (K Units) by Company (2015-2020)
Table 40. United States Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
Table 41. United States Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 42. United States Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 43. United States Antibacterial (Drug) Resistance Sales (K Units) by Application (2015-2020)
Table 44. United States Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)
Table 45. Europe Antibacterial (Drug) Resistance Sales (K Units) by Company (2015-2020)
Table 46. Europe Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
Table 47. Europe Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 48. Europe Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 49. Europe Antibacterial (Drug) Resistance Sales (K Units) by Application (2015-2020)
Table 50. Europe Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 51. China Antibacterial (Drug) Resistance Sales (K Units) by Company (2015-2020)
Table 52. China Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
Table 53. China Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 54. China Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 55. China Antibacterial (Drug) Resistance Sales (K Units) by Application (2015-2020)
Table 56. China Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)
Table 57. Japan Antibacterial (Drug) Resistance Sales (K Units) by Company (2015-2020)
Table 58. Japan Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
Table 59. Japan Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 60. Japan Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 61. Japan Antibacterial (Drug) Resistance Sales (K Units) by Application (2015-2020)
Table 62. Japan Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Antibacterial (Drug) Resistance Sales (K Units) by Company (2015-2020)
Table 64. Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 66. Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 68. Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)
Table 69. India Antibacterial (Drug) Resistance Sales (K Units) by Company (2015-2020)
Table 70. India Antibacterial (Drug) Resistance Sales Market Share by Company (2015-2020)
Table 71. India Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 72. India Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 73. India Antibacterial (Drug) Resistance Sales (K Units) by Application (2015-2020)
Table 74. India Antibacterial (Drug) Resistance Sales Market Share by Application (2015-2020)
Table 75. Melinta Therapeutics Corporation Information
Table 76. Melinta Therapeutics Description and Business Overview
Table 77. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Melinta Therapeutics Antibacterial (Drug) Resistance Product
Table 79. Melinta Therapeutics Recent Development
Table 80. Allergan Corporation Information
Table 81. Allergan Description and Business Overview
Table 82. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Allergan Antibacterial (Drug) Resistance Product
Table 84. Allergan Recent Development
Table 85. Merck Corporation Information
Table 86. Merck Description and Business Overview
Table 87. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Merck Antibacterial (Drug) Resistance Product
Table 89. Merck Recent Development
Table 90. Abbott Laboratories Corporation Information
Table 91. Abbott Laboratories Description and Business Overview
Table 92. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Abbott Laboratories Antibacterial (Drug) Resistance Product
Table 94. Abbott Laboratories Recent Development
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Pfizer Antibacterial (Drug) Resistance Product
Table 99. Pfizer Recent Development
Table 100. GSK Corporation Information
Table 101. GSK Description and Business Overview
Table 102. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. GSK Antibacterial (Drug) Resistance Product
Table 104. GSK Recent Development
Table 105. PENDOPHARM Corporation Information
Table 106. PENDOPHARM Description and Business Overview
Table 107. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. PENDOPHARM Antibacterial (Drug) Resistance Product
Table 109. PENDOPHARM Recent Development
Table 110. Absynth Biologics Corporation Information
Table 111. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 112. Absynth Biologics Description and Business Overview
Table 113. Absynth Biologics Antibacterial (Drug) Resistance Product
Table 114. Absynth Biologics Recent Development
Table 115. Achaogen Corporation Information
Table 116. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Achaogen Description and Business Overview
Table 118. Achaogen Antibacterial (Drug) Resistance Product
Table 119. Achaogen Recent Development
Table 120. Acino Holdings Corporation Information
Table 121. Acino Holdings Description and Business Overview
Table 122. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 123. Acino Holdings Antibacterial (Drug) Resistance Product
Table 124. Acino Holdings Recent Development
Table 125. Aventis Pharma Corporation Information
Table 126. Aventis Pharma Description and Business Overview
Table 127. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 128. Aventis Pharma Antibacterial (Drug) Resistance Product
Table 129. Aventis Pharma Recent Development
Table 130. Austell Laboratories Corporation Information
Table 131. Austell Laboratories Description and Business Overview
Table 132. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 133. Austell Laboratories Antibacterial (Drug) Resistance Product
Table 134. Austell Laboratories Recent Development
Table 135. Assembly Biosciences Corporation Information
Table 136. Assembly Biosciences Description and Business Overview
Table 137. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 138. Assembly Biosciences Antibacterial (Drug) Resistance Product
Table 139. Assembly Biosciences Recent Development
Table 140. Arpida Corporation Information
Table 141. Arpida Description and Business Overview
Table 142. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 143. Arpida Antibacterial (Drug) Resistance Product
Table 144. Arpida Recent Development
Table 145. Demuris Corporation Information
Table 146. Demuris Description and Business Overview
Table 147. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 148. Demuris Antibacterial (Drug) Resistance Product
Table 149. Demuris Recent Development
Table 150. Evolva Holding Corporation Information
Table 151. Evolva Holding Description and Business Overview
Table 152. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 153. Evolva Holding Antibacterial (Drug) Resistance Product
Table 154. Evolva Holding Recent Development
Table 155. ContraFect Corporation Information
Table 156. ContraFect Description and Business Overview
Table 157. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 158. ContraFect Antibacterial (Drug) Resistance Product
Table 159. ContraFect Recent Development
Table 160. Cerexa Corporation Information
Table 161. Cerexa Description and Business Overview
Table 162. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 163. Cerexa Antibacterial (Drug) Resistance Product
Table 164. Cerexa Recent Development
Table 165. InterMune Corporation Information
Table 166. InterMune Description and Business Overview
Table 167. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 168. InterMune Antibacterial (Drug) Resistance Product
Table 169. InterMune Recent Development
Table 170. Isis Pharmaceuticals Corporation Information
Table 171. Isis Pharmaceuticals Description and Business Overview
Table 172. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 173. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product
Table 174. Isis Pharmaceuticals Recent Development
Table 175. Lyndra Corporation Information
Table 176. Lyndra Description and Business Overview
Table 177. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 178. Lyndra Antibacterial (Drug) Resistance Product
Table 179. Lyndra Recent Development
Table 180. Microbecide Corporation Information
Table 181. Microbecide Description and Business Overview
Table 182. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 183. Microbecide Antibacterial (Drug) Resistance Product
Table 184. Microbecide Recent Development
Table 185. Morphochem Corporation Information
Table 186. Morphochem Description and Business Overview
Table 187. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 188. Morphochem Antibacterial (Drug) Resistance Product
Table 189. Morphochem Recent Development
Table 190. Nabriva Therapeutics Corporation Information
Table 191. Nabriva Therapeutics Description and Business Overview
Table 192. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 193. Nabriva Therapeutics Antibacterial (Drug) Resistance Product
Table 194. Nabriva Therapeutics Recent Development
Table 195. NanoSafe Coatings Corporation Information
Table 196. NanoSafe Coatings Description and Business Overview
Table 197. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 198. NanoSafe Coatings Antibacterial (Drug) Resistance Product
Table 199. NanoSafe Coatings Recent Development
Table 200. Novexel Corporation Information
Table 201. Novexel Description and Business Overview
Table 202. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 203. Novexel Antibacterial (Drug) Resistance Product
Table 204. Novexel Recent Development
Table 205. Osel Corporation Information
Table 206. Osel Description and Business Overview
Table 207. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 208. Osel Antibacterial (Drug) Resistance Product
Table 209. Osel Recent Development
Table 210. VenatoRx Pharmaceuticals Corporation Information
Table 211. VenatoRx Pharmaceuticals Description and Business Overview
Table 212. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 213. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product
Table 214. VenatoRx Pharmaceuticals Recent Development
Table 215. AAIPharma Services Corporation Information
Table 216. AAIPharma Services Description and Business Overview
Table 217. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 218. AAIPharma Services Antibacterial (Drug) Resistance Product
Table 219. AAIPharma Services Recent Development
Table 220. ANTABIO Corporation Information
Table 221. ANTABIO Description and Business Overview
Table 222. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 223. ANTABIO Antibacterial (Drug) Resistance Product
Table 224. ANTABIO Recent Development
Table 225. Production Base and Market Concentration Rate of Raw Material
Table 226. Key Suppliers of Raw Materials
Table 227. Antibacterial (Drug) Resistance Distributors List
Table 228. Antibacterial (Drug) Resistance Customers List
Table 229. Market Key Trends
Table 230. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 231. Key Challenges
Table 232. Research Programs/Design for This Report
Table 233. Key Data Information from Secondary Sources
Table 234. Key Data Information from Primary Sources
List of Figures
Figure 1. Antibacterial (Drug) Resistance Product Picture
Figure 2. Global Antibacterial (Drug) Resistance Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Antibacterial (Drug) Resistance Market Share by Application in 2020 & 2026
Figure 6. Complicated Urinary Tract Infection (CUTI) Examples
Figure 7. Complicated Intra-Abdominal Infections (CIAI) Examples
Figure 8. Blood Stream Infections (BSI) Examples
Figure 9. Clostridium Difficile Infections (CDI) Examples
Figure 10. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Examples
Figure 11. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Examples
Figure 12. Community Acquired Bacterial Pneumonia (CABP) Examples
Figure 13. Global Antibacterial (Drug) Resistance Sales (K Units) Growth Rate (2015-2026)
Figure 14. Global Antibacterial (Drug) Resistance Revenue (US$ Million) Growth Rate (2015-2026)
Figure 15. Global Antibacterial (Drug) Resistance Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 16. Global Antibacterial (Drug) Resistance Revenue Market Share by Region: 2015 VS 2020
Figure 17. Global Antibacterial (Drug) Resistance Revenue Market Share by Region: 2021 VS 2026
Figure 18. United States Antibacterial (Drug) Resistance Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. United States Antibacterial (Drug) Resistance Sales (K Units) Growth Rate (2015-2026)
Figure 20. Europe Antibacterial (Drug) Resistance Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Europe Antibacterial (Drug) Resistance Sales (Million USD) Growth Rate (2015-2026)
Figure 22. China Antibacterial (Drug) Resistance Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. China Antibacterial (Drug) Resistance Sales (Million USD) and Growth Rate (2015-2026)
Figure 24. Japan Antibacterial (Drug) Resistance Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. Japan Antibacterial (Drug) Resistance Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Southeast Asia Antibacterial (Drug) Resistance Revenue (Million USD) Growth Rate (2015-2026)
Figure 27. Southeast Asia Antibacterial (Drug) Resistance Sales (Million USD) Growth Rate (2015-2026)
Figure 28. India Antibacterial (Drug) Resistance Revenue (Million USD) Growth Rate (2015-2026)
Figure 29. India Antibacterial (Drug) Resistance Sales (Million USD) Growth Rate (2015-2026)
Figure 30. Global 5 Largest Antibacterial (Drug) Resistance Players Market Share by Revenue in Antibacterial (Drug) Resistance 2015 & 2019
Figure 31. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 32. Global Antibacterial (Drug) Resistance Revenue Share by Type (2015-2020)
Figure 33. Global Antibacterial (Drug) Resistance Revenue Growth Rate by Type in 2015 & 2019
Figure 34. Global Antibacterial (Drug) Resistance Revenue Share by Application (2015-2020)
Figure 35. Global Antibacterial (Drug) Resistance Revenue Growth Rate by Application in 2015 & 2019
Figure 36. United States Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 37. United States Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 38. Europe Antibacterial (Drug) Resistance Sales Market Share by Company in 2019
Figure 39. Europe Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 40. Europe Antibacterial (Drug) Resistance Sales Market Share by Application in 2019
Figure 41. China Antibacterial (Drug) Resistance Sales Market Share by Company in 2019
Figure 42. China Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 43. China Antibacterial (Drug) Resistance Sales Market Share by Application in 2019
Figure 44. Japan Antibacterial (Drug) Resistance Sales Market Share by Company in 2019
Figure 45. Japan Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 46. Japan Antibacterial (Drug) Resistance Sales Market Share by Application in 2019
Figure 47. Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Company in 2019
Figure 48. Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 49. Southeast Asia Antibacterial (Drug) Resistance Sales Market Share by Application in 2019
Figure 50. India Antibacterial (Drug) Resistance Sales Market Share by Company in 2019
Figure 51. India Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 52. India Antibacterial (Drug) Resistance Sales Market Share by Application in 2019
Figure 53. Melinta Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. GSK Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. PENDOPHARM Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Absynth Biologics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Achaogen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Acino Holdings Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Aventis Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Austell Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Assembly Biosciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Arpida Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Demuris Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Evolva Holding Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. ContraFect Total Revenue (US$ Million): 2019 Compared with 2018
Figure 70. Cerexa Total Revenue (US$ Million): 2019 Compared with 2018
Figure 71. InterMune Total Revenue (US$ Million): 2019 Compared with 2018
Figure 72. Isis Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 73. Lyndra Total Revenue (US$ Million): 2019 Compared with 2018
Figure 74. Microbecide Total Revenue (US$ Million): 2019 Compared with 2018
Figure 75. Morphochem Total Revenue (US$ Million): 2019 Compared with 2018
Figure 76. Nabriva Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 77. NanoSafe Coatings Total Revenue (US$ Million): 2019 Compared with 2018
Figure 78. Novexel Total Revenue (US$ Million): 2019 Compared with 2018
Figure 79. Osel Total Revenue (US$ Million): 2019 Compared with 2018
Figure 80. VenatoRx Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 81. AAIPharma Services Total Revenue (US$ Million): 2019 Compared with 2018
Figure 82. ANTABIO Total Revenue (US$ Million): 2019 Compared with 2018
Figure 83. Key Raw Materials Price Trend
Figure 84. Manufacturing Cost Structure of Antibacterial (Drug) Resistance
Figure 85. Manufacturing Process Analysis of Antibacterial (Drug) Resistance
Figure 86. Antibacterial (Drug) Resistance Industrial Chain Analysis
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Porter's Five Forces Analysis
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed